💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Bayer gets tentative ruling for new trial in weed-killer case

Published 10/10/2018, 09:19 PM
© Reuters. Plaintiff Dewayne Johnson leaves the courtroom following a post-trial hearing at the Superior Court in San Francisco
BAYGN
-
MON
-

By Jim Christie

SAN FRANCISCO (Reuters) - Bayer AG's (DE:BAYGn) Monsanto (NYSE:MON) unit received a tentative ruling for a new trial on the $250 million in punitive damages awarded by a jury to a groundskeeper who alleged the company's glyphosate-based weed killers, including Roundup, caused his cancer.

According to a Wednesday court filing in San Francisco's Superior Court of California, Judge Suzanne Bolanos was considering whether to grant the company's motion for a new trial on the punitive damages.

The judge's ruling, granting a new trial on the punitive damages, is tentative and was being discussed at a court hearing underway on Wednesday. The Aug. 10 award to Dewayne Johnson included $39 million in compensatory damages.

The combined $289 million verdict marked the first decision finding that Monsanto had failed to warn consumers of the alleged cancer risks posed by glyphosate, the world's most widely used weed-killer.

Bayer, which bought Monsanto earlier this year for $63 billion, faces more than 8,000 similar lawsuits in the United States.

The German company has denied the allegation and has said that decades of real-world application and scientific studies have shown the chemical to be safe for human use.

Investors have raised concerns over the litigation risk, with Bayer shares falling sharply after the decision and still trading some 20 percent below their pre-verdict level at 75.10 euros ($86.57) on Wednesday.

In September 2017, the U.S. Environmental Protection Agency concluded a decades-long assessment of glyphosate risks and found that the chemical was not a likely carcinogen to humans. However, in 2015 the cancer unit of the World Health Organization classified glyphosate as "probably carcinogenic to humans."

On Wednesday, the judge said that Johnson had failed to meet his burden of producing clear and convincing evidence of malice or oppression by Monsanto, a requirement for allowing a jury to award punitive damages.

Monsanto had asked Bolanos in court filings on Sept. 18 to set aside the entire verdict or, in the alternative, reduce the award or grant a new trial.

The judge's order said the company's request for an entire new trial that includes liability grounds would also be discussed during Wednesday's court hearing.

Bayer did not immediately respond to a request for comment.

Lawyers for Johnson said they would only comment after Wednesday's court hearing concludes.

Johnson's case, filed in 2016, was fast-tracked for trial due to the severity of his non-Hodgkin's lymphoma, a cancer of the lymph system, that he alleged was caused by years of exposure to Roundup and Ranger Pro, another Monsanto herbicide that contains glyphosate.

© Reuters. Plaintiff Dewayne Johnson leaves the courtroom following a post-trial hearing at the Superior Court in San Francisco

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.